Genomma Lab Internacional SAB de CV Class B

As of June 30, 2026, Genomma Lab International SAB DE CV carries a market capitalization of 812.59M, placing it among publicly traded companies globally. Its enterprise value stands at 1.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genomma Lab International SAB DE CV's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Genomma Lab International SAB DE CV has 977.75M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Genomma Lab International SAB DE CV maintains a current ratio of 1.84, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Genomma Lab International SAB DE CV recorded 31.94M in income tax expense.

As of the close on October 16, 2026, Genomma Lab International SAB DE CV's stock has declined approximately 22.74% over the past 52 weeks. The 50-day moving average sits at 0.96, while the 200-day moving average is 0.97.

As of June 30, 2026, Genomma Lab International SAB DE CV holds 139.38M in cash and equivalents against 444.84M in total debt, resulting in a net debt position of 121.96M. Total book value stands at 674.03M, with working capital of 343.87M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Genomma Lab International SAB DE CV paid dividends of 0.03 per share.

Genomma Lab International SAB DE CV's most recent stock split took place on August 3, 2010 with a 1:2 split ratio.